Puma Biotechnology Inc
TheStreet's Adam Feuerstein, arguably the most noted biotech reporter around,
Earlier Wednesday afternoon, sources close to Puma's secondary offering
Benzinga Pro heard from another source close to the deal that Puma Biotech is discussing a debt deal instead of an equity deal. For a little background, a debt deal involves borrowing money to be repaid, plus interest; Equity deal involves raising money by selling interests in the company.
Shares of Puma Biotech traded recently at $42.85, down more than 18 percent on the day.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.